Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Norton Pulmonary Specialists

Neither a doctor nor a teaching hospital

Research payments

$603,893

35 payments

Through program year 2025, Norton Pulmonary Specialists is reported as receiving $603,893 in research payments, across 35 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $257,893 12
2024 Research $36,830 5
2023 Research $22,738 8
2022 Research $229,606 7
2021 Research $53 1
2020 Research $56,775 2

Breakdown

Who paid Research payments · program years 2020–2025
  1. Merck Sharp & Dohme Corporation $468,607 17 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $77,318 14 payments
  3. Actelion Pharmaceuticals, Ltd $56,775 2 payments
  4. E.R. Squibb & Sons, L.L.C. $1,141 1 payment
  5. Insmed, Inc. $53 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organization WHO Functional Class FC III o $116,744 1 payment
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Aterial Hypertension PAH Therapy for the Treatment of PAH $116,315 3 payments
  3. A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF $115,299 5 payments
  4. BAY 632521, RiOciguAt UseRs Registry The ROAR registry $58,929 8 payments
  5. OPsumit Users Registry $56,775 2 payments
  6. A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF $28,028 1 payment
  7. A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF $23,201 1 payment
  8. An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038 $19,870 1 payment
  9. Roar $18,390 6 payments
  10. A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7962 Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on $16,355 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record